Prostate Cancer, Renal Cancer
Conditions
Brief summary
An phase I study to evaluate the uptake of \[68Ga\]P16-093 in known or suspected metastatic prostate or renal cancer to establish the feasibility of using \[68Ga\]P16-093 to image PSMA expressing cancer. Measurement of the whole body biodistribution of \[68Ga\]P16-093 in prostate cancer patients post primary curative-intent treatment with stable PSA to generate human radiation dosimetry data.
Interventions
DRUG[68Ga]P16-093
Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
Sponsors
Five Eleven Pharma, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DYNAMIC GROUP: Inclusion Criteria: 1. Participants will be male ≥ 18 years of age 2. History of histologically confirmed cancer that meets criteria for either a) or b) 1. Prostate cancer with known or suspected recurrent or metastatic disease based on clinical imaging (e.g. CT, bone scan, MRI, ultrasound, FDG PET/CT, FACBC PET/CT) within 12 months of screening. If subject is post curative-intent local treatment (e.g. radical prostatectomy, local radiotherapy, brachytherapy) they must have had no intervening change in cancer treatment. OR 2. Renal Cell cancer with known or suspected metastatic disease based on clinical imaging (e.g. CT, bone scan, MRI, ultrasound, FDG PET/CT) 3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Exclusion criteria
1. Estimated creatinine clearance (eGFR) \< 30 mL/min (calculated from serum creatinine result within 30 days of screening) 2. Chemotherapy or radiation therapy within 2 weeks of screening 3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician 4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful completion of the study BIODISTRIBUTION GROUP: Inclusion Criteria: 1. Participants will be male ≥ 18 years of age 2. History of prostate cancer that is post curative-intent local treatment (e.g. radical prostatectomy, local radiotherapy, brachytherapy) with clinical PSA levels that meet one of the following criteria 1. Post-Prostatectomy (with or without adjuvant RT): PSA level that is \< 0.2 ng/mL measured over at least 2 consecutive tests OR 2. Post-Radiotherapy: PSA level that has not risen from nadir measured over at least 2 consecutive tests 3. If clinical imaging (e.g. bone scan, CT, MRI, ultrasound, PET/CT) has been done within 3 months of screening as part of standard clinical surveillance it must be negative or equivocal for sites of recurrent or metastatic disease (clinical imaging is not required for enrollment) 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Uptake of [68Ga]P16-093 in metastatic prostate and renal cancer | 0.5 - 3 hours after injection | Standard uptake value (SUV) of \[68Ga\]P16-093 in apparent lesions detected by PET/CT. |
| Radiation dosimetry of [68Ga]P16-093 in patients with a history of prostate cancer | up to 3 hours after injection | Radiation dosimetry (organ absorbed dose and effective dose) will be determined using region of interest data drawn on sequential PET/CT images and data from blood and / or urine obtained during scanning. |
Countries
United States
Outcome results
None listed